ImmunityBio, Inc. (IBRX) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$113.3M

Net Income/Loss (FY2025)

-$351.5M

Total Assets (FY2025)

$501.9M

Total Equity (FY2025)

-$499.6M

Cash Flows from Operating Activities (FY2025)

-$304.9M

Source: ImmunityBio, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.